November 2008 PBAC Outcomes - Deferrals

PDF Printable version this page (PDF 19 KB)

table showing deferrals made by the PBAC - November

Drug and Form

Drug use and Type

Listing Requested by Sponsor

PBAC Outcome and Comment

Dornase alfa, solution for inhalation 2.5 mg (2,500 units) in 2.5 mL, (Pulmozyme®)

Roche Products Pty Ltd

Minor submission
Helps manage the respiratory complications of cystic fibrosis Seeks changes to the current restriction wording to include use in patients aged < 5 years and the inclusion of grandfather clauses. Deferred to allow further dialogue with the Thoracic Society of Australia and New Zealand (TSANZ) and other stakeholders.
Sponsor’s comments: The sponsor did not provide any comments.